Dr. Seiko Brown concentrates her practice on a variety of life science and pharmaceutical technology areas including immunology, oncology, pharmacology, nanomedicine, gene therapy, and biotech business.
Prior to joining Baker Donelson, Dr. Brown was a senior analyst at Celdara Medical, where she managed the company's intellectual property portfolio, performed due diligence on technology seeds for potential licensing deals, conducted freedom-to-operate and landscape analyses, and prepared NIH Small Business Innovation Research grant applications. She has assessed hundreds of therapeutic and diagnostic technologies in a wide range of disease space including cancer, autoimmune diseases, infectious diseases, allergy, metabolic and cardiac diseases, neural diseases, and rare and neglected diseases. Dr. Brown also assisted intellectual property firms in Philadelphia and Japan and the technology licensing office of a research university in Japan by providing technical translation and prior art search services.
Dr. Brown received her Ph.D. in Microbiology and Immunology from Dartmouth College. Her thesis work was performed in the laboratory of Professor Steven Fiering and investigated anti-tumor immune responses and therapeutic effects elicited by local hyperthermia induced by iron-oxide nanoparticles and an alternating magnetic field. In collaboration with AspenMedisys, she also analyzed the impact of different surface modifications of nanoparticles on the interaction with immune cells.
Dr. Brown received her B.S. in Pharmaceutical Sciences from the University of Tokyo and obtained the Japanese pharmacist license upon graduation. During her senior year, she worked in the laboratory of Professor Tatsuro Irimura and performed screening of glycosylation-dependent monoclonal antibodies against a cancer antigen, Muc21.